Investigational drug · Phase 3
HRS-9231
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions, For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS).
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
6
Any phase or sponsor naming "HRS-9231"
First trial start
2024
Dec 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-9231", any sponsor or status.
Conditions studied
As listed on its trial records.
- For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
- For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-9231" as an intervention, largest first.
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) LesionsPivotal-lookingCompleted
Shanghai Shengdi Pharmaceutical Co., LtdIndustry
NCT07275723 · 309 participants · Start Nov 14, 2025 · Primary completion Apr 18, 2026
Drug: HRS-9231 Injection; Gadobutrol Injection · For: For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)
Sites: Shanghai, China; Chengdu, China
- A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) LesionsPivotal-lookingCompleted
Shanghai Shengdi Pharmaceutical Co., LtdIndustry
NCT07275814 · 250 participants · Start Nov 17, 2025 · Primary completion Jun 17, 2026
Drug: HRS-9231 Injection; Gadobutrol Injection · For: For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Sites: Beijing, China; Zhengzhou, China
- A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord ConditionsNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06731829 · 78 participants (planned) · Start Dec 2024 · Primary completion Apr 2025
Drug: HRS-9231; Gadobutrol · For: For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Sites: Beijing, China
Shanghai Shengdi Pharmaceutical Co., LtdIndustry
NCT06657560 · 41 participants · Start Oct 14, 2024 · Primary completion Jul 3, 2025
Drug: HRS-9231 · For: Contrast-Enhanced Magnetic Resonance Imaging Detection
Sites: Jinan, China
Shanghai Shengdi Pharmaceutical Co., LtdIndustry
NCT07123376 · 40 participants · Start Jun 5, 2024 · Primary completion Oct 6, 2024
Drug: HRS-9231; Placebo · For: Healthy Volunteers
Sites: Suzhou, China
Atridia Pty Ltd.Industry
NCT06519981 · 20 participants · Start Aug 21, 2024 · Primary completion Sep 29, 2024
Drug: HRS-9231or matching placebo · For: MRI
Sites: Perth, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.
Han Q, Zhang R, He Y, et al. · Clin Pharmacokinet 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.